Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGyre Therapeutics Inc.

Gyre Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.26 USD 0.03 ( 0.71%)
Last update at 2026-11-11T21:00:00Z
VOLUME
130298
Market Cap
709.37M

Momentum Score

…

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.22
Low
4.38
High
52 Week Price Range
5.44
Low
9.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Gyre Therapeutics is limited; the company is listed on NASDAQ under the ticker GYRE and public filings provide few operational details. Long-term growth may depend on progress with any development-stage assets, successful regulatory or partnership outcomes, and continued access to capital, which could make the stock of interest to investors seeking high-risk, high-reward exposure to small-cap life sciences.

The principal risks are scarce public disclosure and low liquidity, together with execution, regulatory and financing uncertainty common to early-stage biotechnology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.23
Dividend Yield
-
Revenue TTM
109.82M
Revenue Per Share
1.17
Gross Profit TTM
103.01M
Debt / Equity
0.01
ROE
-17.44%
Net Debt
-36.13M
ROCE
7.77%
Diluted EPS TTM
-0.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 14.44M 23.22M -76.97M -7.89M -87.93M
Minority interest -4.85M -5.81M -7.45M -2.01M -
Net income 5.03M 12.09M -92.93M 2.30M -87.93M
Selling general administrative 20.80M 16.11M 14.66M 17.37M 18.96M
Selling and marketing expenses 65.18M 57.51M 61.16M 54.24M 44.65M
Gross profit 111.17M 101.87M 108.81M -0.00M -0.04M
Reconciled depreciation 2.52M 1.59M 1.11M 1.13M 1.93M
Ebit 11.49M 16.23M 114.92M -8.61M -87.89M
Ebitda 14.01M 17.82M 116.03M -52.15M -87.60M
Depreciation and amortization 2.52M 1.59M 1.11M -43.54M 0.29M
Operating income 11.49M 16.16M -67.23M -8.61M -87.89M
Other operating expenses 105.10M 89.59M 94.24M 31.20M 95.23M
Interest expense - - - 0.72M 0.04M
Tax provision 4.56M 5.32M 8.52M 5.10M 6.17M
Interest income 1.75M 1.55M - 4.88M 0.38M
Net interest income 1.75M 1.55M 1.04M 0.73M 0.26M
Income tax expense -4.56M 5.32M 8.52M 0.35M -0.04M
Total revenue 116.59M 105.76M 113.45M 0.79M 7.34M
Total operating expenses 99.69M 85.71M 89.60M 30.40M 87.85M
Cost of revenue 5.42M 3.88M 4.64M 0.80M 7.38M
Total other income expense net 2.95M 7.05M -97.22M 0.72M -0.04M
Net income from continuing ops 9.88M 17.90M -85.48M 4.31M 23.44M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 166.13M 125.41M 116.54M 709.59M 540.87M
Intangible assets 4.73M 1.71M 0.20M 161.25M 132.35M
Other current assets 2.83M 2.62M 1.04M - -
Total liab 23.85M 27.00M 102.59M 85.12M 76.04M
Total stockholder equity 106.03M 63.32M -15.83M 624.47M 464.83M
Other current liab 14.57M 15.71M 19.40M - -
Common stock 0.00M 0.09M 0.08M - -
Capital stock 0.09M 0.09M 0.08M 61.32M 61.32M
Retained earnings -68.43M -73.45M -85.54M 283.04M 147.11M
Cash 37.07M 11.81M 33.51M 163.42M 166.29M
Total current liabilities 18.29M 19.52M 20.05M 78.07M 65.63M
Current deferred revenue 0.01M 0.16M 0.08M - -
Net debt -36.13M -10.21M -33.10M - -
Short term debt 0.64M 0.71M 0.21M - -
Short long term debt total 0.94M 1.60M 0.41M - -
Other stockholder equity 172.14M 136.19M 3.65M - -
Total current assets 102.37M 64.79M 57.22M 333.90M 285.89M
Long term investments 23.52M 24.57M 23.43M 51.50M 0.00M
Short term investments 15.36M 14.86M - 10.60M 2.48M
Net receivables 36.95M 29.15M 16.84M 108.75M 64.06M
Inventory 10.17M 6.34M 4.28M 42.64M 36.46M
Accounts payable 0.12M 0.11M 0.35M 0.85M 1.60M
Accumulated other comprehensive income 2.32M 0.50M 1.45M - -
Non currrent assets other 27.43M 3.03M 5.72M - -
Non current assets total 63.76M 60.62M 59.32M 375.69M 254.98M
Capital lease obligations 0.94M 1.60M 0.41M 4.99M 7.83M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.42M -19.88M -19.76M -13.81M -8.19M
Total cashflows from investing activities -0.47M -19.88M - - -
Total cash from financing activities 24.38M 2.10M 2.50M -45.01M 49.55M
Net income 9.88M 17.90M -85.48M -8.24M -87.93M
Change in cash 25.26M -21.70M 8.33M -22.68M 13.99M
Begin period cash flow 11.81M 33.51M 25.18M 44.35M 30.36M
End period cash flow 37.07M 11.81M 33.51M 21.67M 44.35M
Total cash from operating activities 1.01M -3.64M 25.89M -33.10M -83.75M
Issuance of capital stock 23.51M 0.77M 2.50M 0.00M -
Depreciation 2.48M 1.59M 1.11M 0.23M 0.29M
Other cashflows from investing activities 0.69M -0.41M - - -
Dividends paid - - - 45.03M 0.00M
Change to inventory -3.63M -2.14M 1.75M -0.88M 3.88M
Change to account receivables -11.95M -9.29M 1.40M 1.62M 1.50M
Other cashflows from financing activities -1.49M 1.33M 2.50M 0.02M 0.30M
Capital expenditures 1.19M 3.13M 8.59M 5.00M 0.84M
Change in working capital -15.55M -15.69M 7.46M -4.95M 0.48M
Stock based compensation 7.16M 0.83M 7.28M 13.37M 3.40M
Other non cash items -1.84M -7.27M 96.68M -21.48M 3.89M
Free cash flow -0.18M -6.77M 17.31M -38.09M -84.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GYRE
Gyre Therapeutics Inc.		 0.03
0.71%		 4.26 - 188.68 6.46 6.59 5.83 131.00
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Gyre Therapeutics Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

12730 High Bluff Drive, San Diego, CA, United States, 92130

858-284-0115

https://www.gyretx.com

625

Name Title Year Born
Dr. Han Ying Ph.D. CEO & Director NA
Mr. Songjiang Ma President & Director NA
Ms. Ruoyu Chen Interim Chief Financial Officer 1970
Mr. Weiguo Ye Chief Operating Officer NA
Ms. Seline E. Miller CPA Senior Vice President of Finance 1969
Mr. Songjiang Ma President & Director 1956
Ms. Ruoyu Chen Chief Financial Officer 1971
Mr. Weiguo Ye Chief Operating Officer 1978
Dr. Han Ying Ph.D. Senior Vice President of Science 1966
Mr. Ping Zhang Interim CEO & Executive Chair 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…